Want to see EMMA full AI Analyst Report?
Total Valuation
Emmaus Life Sciences has a market cap or net worth of $4.79M. The enterprise value is $28.94.
Market Cap$4.79M
Enterprise Value$28.94
Share Statistics
Emmaus Life Sciences has 70,188,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,188,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Emmaus Life Sciences’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is -1.23%.
Return on Equity (ROE)0.12
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-1.23%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee377.36K
Profits Per Employee-227.03K
Employee Count33
Asset Turnover0.58
Inventory Turnover0.55
Valuation Ratios
The current PE Ratio of Emmaus Life Sciences is ―. Emmaus Life Sciences’s PEG ratio is -0.00542.
PE Ratio―
PS Ratio0.07
PB Ratio-0.01
Price to Fair Value-0.01
Price to FCF-69.38
Price to Operating Cash Flow1.09
PEG Ratio-0.00542
Income Statement
In the last 12 months, Emmaus Life Sciences had revenue of 12.45M and earned -7.49M in profits. Earnings per share was -0.12.
Revenue12.45M
Gross Profit11.60M
Operating Income231.00K
Pretax Income-7.48M
Net Income-7.49M
EBITDA-310.00K
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was 3.97M and capital expenditures -2.00K, giving a free cash flow of 3.96M billion.
Operating Cash Flow3.97M
Free Cash Flow3.96M
Free Cash Flow per Share0.06
Dividends & Yields
Emmaus Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta57.78
52-Week Price Change369.23%
50-Day Moving Average0.03
200-Day Moving Average0.01
Relative Strength Index (RSI)60.51
Average Volume (3m)231.49K
Important Dates
Emmaus Life Sciences upcoming earnings date is Nov 18, 2026, Before Open (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Emmaus Life Sciences as a current ratio of 0.11, with Debt / Equity ratio of -46.13%
Current Ratio0.11
Quick Ratio0.09
Debt to Market Cap37.00
Net Debt to EBITDA-98.17
Interest Coverage Ratio0.03
Taxes
In the past 12 months, Emmaus Life Sciences has paid 9.00K in taxes.
Income Tax9.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Emmaus Life Sciences EV to EBITDA ratio is -100.85, with an EV/FCF ratio of -2.61K.
EV to Sales2.51
EV to EBITDA-100.85
EV to Free Cash Flow-2.61K
EV to Operating Cash Flow-2.84K
Balance Sheet
Emmaus Life Sciences has $2.81M in cash and marketable securities with $30.52M in debt, giving a net cash position of -$27.72M billion.
Cash & Marketable Securities$2.81M
Total Debt$30.52M
Net Cash-$27.72M
Net Cash Per Share-$0.39
Tangible Book Value Per Share-$0.99
Margins
Gross margin is 93.60%, with operating margin of 1.85%, and net profit margin of -60.16%.
Gross Margin93.60%
Operating Margin1.85%
Pretax Margin-60.09%
Net Profit Margin-60.16%
EBITDA Margin-2.49%
EBIT Margin-2.80%
Analyst Forecast
The average price target for Emmaus Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast10.98%
EPS Growth Forecast-72.08%